Most Clicked StoriesMore >


Ambrx to be purchased by WuXi, other firms

BIO SmartBrief | May 26, 2015

San Diego-based Ambrx will be acquired by a consortium that includes Wuxi PharmaTech. The acquisition, which is expected to be completed sometime in the next several weeks, will give WuXi access to Ambrx's antibody-drug conjugate technology and its biologics development expertise. BioPharmaReporter.com (05/22)


AbbVie wraps up purchase of Pharmacyclics for $21B

BIO SmartBrief | May 27, 2015

Juno, Editas sign up-to $737M deal to develop cancer treatments

BIO SmartBrief | May 28, 2015

European agency releases draft guidelines for gene therapies

BIO SmartBrief | May 26, 2015

EU recommends approval of Merck's Keytruda for melanoma

BIO SmartBrief | May 26, 2015

J&J to seek regulatory approval for 10 drugs in next 4 years

BIO SmartBrief | May 22, 2015

Boehringer signs antibody-drug-development deal with Eureka

BIO SmartBrief | May 22, 2015

House panel OKs 21st Century Cures measure

BIO SmartBrief | May 22, 2015

Irritable bowel syndrome drugs from Actavis, Valeant receive FDA approval

BIO SmartBrief | May 28, 2015

Aspen sells unit to Strides Arcolab Limited

BIO SmartBrief | May 22, 2015


Find BIO SmartBrief Issues by Date:



BIO News More >


BIO announces new member benefit -- Executive Liability Protection though Aon Risk Solutions

BIO SmartBrief | May 29, 2015

Join the global biotech community in Philadelphia

BIO SmartBrief | May 29, 2015

BIO announces new member benefit -- Executive Liability Protection through Aon Risk Solutions

BIO SmartBrief | May 28, 2015

Find the experienced biotech talent that your company needs

BIO SmartBrief | May 26, 2015

BIO International Convention -- Register Now

BIO SmartBrief | May 22, 2015




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more